FDA panel to review once-rejected Acadia drug for psychosis
Dive Brief:
After receiving a rejection last year, Acadia said Wednesday that the Food and Drug Administration agreed to review its resubmitted application to expa...
From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment
Continue readingAdvertisement
Advertisement
Advertisement
Advertisement
Advertisement